Aspirin vs. Blood Thinners, a 9-Year Endo Wait Ends & Cyclospora Hits Taco Bell

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Add to cart failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Follow podcast failed

Unfollow podcast failed

Aspirin vs. Blood Thinners, a 9-Year Endo Wait Ends & Cyclospora Hits Taco Bell

Listen for free

View show details

Friday, July 17, 2026 In today’s episode, Dr. Will Flanary / Dr. Glaucomflecken (@drglaucomflecken) and Adam Rose cover the EPCAT III trial, which found that aspirin alone was non-inferior to an initial course of rivaroxaban followed by aspirin for preventing major blood clots after elective hip or knee replacement in predominantly standard-risk patients. They examine NICE’s draft recommendation allowing two rapid endometriosis tests, EndoSure and Endotest, to enter limited NHS use while researchers gather additional real-world evidence. Plus: They discuss a recall involving more than 2.5 million bottles of prednisolone acetate eye drops, the first HAVANA Act compensation payments, the expanding Cyclospora response, and The Pitt leading the 2026 Emmy nominations with 25 nods. (00:00) Intro (01:07) Aspirin vs. Rivaroxaban After Joint Replacement (03:19) NICE Endorses Rapid Endometriosis Tests (05:30) FDA Recall of Prednisolone Eye Drops (06:07) First Havana Syndrome Payments (06:41) Cyclospora Outbreak Reaches Taco Bell (07:10) The Pitt Leads Emmy Nominations Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com. Sources & Media Attributions for Today’s Episode Available At: www.medlinespod.com/sources Medlines is a Human Content Production

No reviews yet